Hack Epilepsy is a two-city hackathon with a single purpose: improving the lives of people with epilepsy. Inspired by patients and driven by science, its goal is to build innovative digital tools for people with epilepsy and their caregivers. Developers, designers and epilepsy experts will come together at two simultaneous hackathons in Brussels and Atlanta from April 24 – 26.
Hack Epilepsy, sponsored by UCB, is an opportunity for you to use your expertise, creativity and specialist skills to build innovative digital tools to break down barriers, bridge gaps and bring new solutions to the challenges of living with epilepsy. Interested? Learn more & register.
In each location, teams will have a chance to win one of three cash prizes, to be divided among participating team members:
- First prize: $6,900
- Second prize: $3,450
- Third prize: $1,150
Don’t know about epilepsy? No problem! Doctors and patients will explain more about epilepsy and what it means to live with unpredictable seizures. You’ll gain all the insight needed to develop meaningful prototype digital solutions which can make a much-needed difference to the epilepsy community.
How it works:
Hack Epilepsy has set four challenges aimed at building an exciting new world. These challenges include:
- Challenge 1: Connecting and Sharing
- Challenge 2: ABC of Epilepsy
- Challenge 3: Seizure Guardian
- Challenge 4: Co-Pilot
Presentations will be evaluated by a judging panel at the close of the hackathon according to:
- Ability to meet real needs of people with epilepsy
- Creativity, innovation and originality
- Feasibility of implementation
- Quality of presentation and demonstration
Why epilepsy?
Epilepsy is a common serious brain disorder that affects 65 million people worldwide – young and old, rich and poor. It leaves no part of daily life untouched. Epilepsy impairs physical, psychological and social functioning and can be fatal. There is a need for new and better digital tools to support people with epilepsy and potentially even save lives.
About UCB:
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is headquartered in Brussels, Belgium and has U.S. offices in Atlanta, U.S. UCB is listed on Euronext Brussels (symbol: UCB).
